Inside Precision Medicine October 22, 2024
CEO Bruce Beutel explains the current limitations of drugging protein combinations and how the platform designs solutions using only one molecule
Bruce Beutel, PhD, who has worked in the drug development industry for over thirty years is ready for a change. He wants to move beyond the single target paradigm, in which a single molecule has a highly targeted effect on the function of one protein.
“The issue with [the single target paradigm] is that when you try to treat complex diseases, particularly diseases of aging or things like diabetes and autoimmune diseases, they’re multi-factorial,” Beutel said to Inside Precision Medicine. “Biology works through the interplay of different proteins affecting each other, doing work together, and compensating for each other—it’s...
Today's Sponsors
Today's Sponsor